ArticleHuman genomics2025
Influence of genetic variants and omega-3 fatty acids on acute myocardial infarction: findings from a prospective cohort study.
Article in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological studies have indicated that elevated levels of omega-3 fatty acids may reduce the risk of acute myocardial infarction (AMI). In contrast, genetic studies and randomized controlled trials have not succeeded in corroborating this protective association. This study aims to clarify how specific genetic variants related to omega-3 fatty acids levels influence their association with incident AMI.
methodsInitially, we performed two-sample Mendelian randomization (MR) and transcriptomics MR to identify causal loci influencing omega-3 fatty acid levels and their subsequent implications on AMI. Subsequently, we applied a series of genetic analyses to uncover pleiotropic loci shared between omega-3 levels and AMI. Furthermore, we utilized the UK Biobank cohort to assess whether genetic polymorphisms impact the correlation between omega-3 fatty acid levels and AMI.
resultsMR analysis identified that increases in genetically predicted omega-3 fatty acid levels are related to an elevated risk of AMI (odds ratio = 1.11, 95% confidence interval [CI] = 1.03–1.19, P = 0.004), with four causal loci (rs7970695, rs10096633, rs12914626, and rs964184) confirmed through transcriptomics MR. Furthermore, we established a significant positive genetic correlation between omega-3 fatty acid levels and AMI (rg = 0.10, P = 0.010), along with two notable pleiotropic loci (rs10455872 and rs112875651). In the UK Biobank cohort (56.6 ± 8.0 years, 55.1% female), elevated omega-3 fatty acid levels were linked to decreased AMI risk following thorough adjustment for confounders (adjusted hazard ratio [aHR] = 0.86, 95% CI = 0.81–0.90, P < 0.001). The most significant protective effect was observed among individuals with the rs964184 [ZNF259] GG genotype (aHR = 0.62, 95% CI = 0.41–0.94, P = 0.023), whereas an attenuation was noted in those carrying the rs964184 CC genotype (aHR = 0.87, 95% CI = 0.82–0.92, P < 0.001, P-interaction = 0.008). Additional genotypic variability, including rs10455872, rs10096633, and rs261339 (proxies for rs12914626), may also influence outcomes, though without significant interactions.
conclusionsThe ZNF259 rs964184 variant possesses the potential to reduce the protective capacity of omega-3 fatty acids against AMI. Future clinical investigations should consider genetic factors and explore the underlying mechanistic pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.